Suppr超能文献

神经纤维瘤病:分子发病机制与作为潜在治疗方法的天然化合物

Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments.

作者信息

Amaravathi Anusha, Oblinger Janet L, Welling D Bradley, Kinghorn A Douglas, Chang Long-Sheng

机构信息

Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States.

Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States.

出版信息

Front Oncol. 2021 Sep 17;11:698192. doi: 10.3389/fonc.2021.698192. eCollection 2021.

Abstract

The neurofibromatosis syndromes, including NF1, NF2, and schwannomatosis, are tumor suppressor syndromes characterized by multiple nervous system tumors, particularly Schwann cell neoplasms. NF-related tumors are mainly treated by surgery, and some of them have been treated by but are refractory to conventional chemotherapy. Recent advances in molecular genetics and genomics alongside the development of multiple animal models have provided a better understanding of NF tumor biology and facilitated target identification and therapeutic evaluation. Many targeted therapies have been evaluated in preclinical models and patients with limited success. One major advance is the FDA approval of the MEK inhibitor selumetinib for the treatment of NF1-associated plexiform neurofibroma. Due to their anti-neoplastic, antioxidant, and anti-inflammatory properties, selected natural compounds could be useful as a primary therapy or as an adjuvant therapy prior to or following surgery and/or radiation for patients with tumor predisposition syndromes, as patients often take them as dietary supplements and for health enhancement purposes. Here we review the natural compounds that have been evaluated in NF models. Some have demonstrated potent anti-tumor effects and may become viable treatments in the future.

摘要

神经纤维瘤病综合征,包括1型神经纤维瘤病(NF1)、2型神经纤维瘤病(NF2)和施万细胞瘤病,是肿瘤抑制综合征,其特征为多发性神经系统肿瘤,尤其是施万细胞肿瘤。与NF相关的肿瘤主要通过手术治疗,其中一些肿瘤曾接受过传统化疗,但效果不佳。分子遗传学和基因组学的最新进展以及多种动物模型的开发,使人们对NF肿瘤生物学有了更好的理解,并有助于靶点识别和治疗评估。许多靶向治疗已在临床前模型和患者中进行评估,但取得的成功有限。一项重大进展是美国食品药品监督管理局(FDA)批准了MEK抑制剂司美替尼用于治疗与NF1相关的丛状神经纤维瘤。由于其抗肿瘤、抗氧化和抗炎特性,对于有肿瘤易感性综合征的患者,某些天然化合物可作为主要治疗方法,或在手术和/或放疗之前或之后作为辅助治疗,因为患者常将其作为膳食补充剂用于增强健康。在此,我们综述了在NF模型中已得到评估的天然化合物。其中一些已显示出强大的抗肿瘤作用,未来可能成为可行的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d2e/8485038/34d6850dd6b9/fonc-11-698192-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验